-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 13, Guilin Sanjin issued an announcement stating that lamotrigine tablets from Hunan Sanjin, a wholly-owned subsidiary, passed the consistency evaluation
.
Lamotrigine is an anti-epileptic drug.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 400 million yuan
.
.
Lamotrigine is an anti-epileptic drug.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 400 million yuan
.
Lamotrigine tablets are a dual sodium channel blocker and glutamate release inhibitor developed by GlaxoSmithKline.
It is mainly used to treat epilepsy.
It was marketed in the United States in 1994 and approved for marketing in China in 1999
.
Lamotrigine tablets from Hunan Sanjin are the first imitation in China
.
It is mainly used to treat epilepsy.
It was marketed in the United States in 1994 and approved for marketing in China in 1999
.
Lamotrigine tablets from Hunan Sanjin are the first imitation in China
.
According to data from Minai.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China’s urban physical pharmacies will have a combined total of more than 400 million yuan in sales of lamotrigine.
The market share of Lanxo SmithKline reaches 86%
.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China’s urban physical pharmacies will have a combined total of more than 400 million yuan in sales of lamotrigine.
The market share of Lanxo SmithKline reaches 86%
.
TOP5 generic names of terminal antiepileptic drugs in physical pharmacies in Chinese cities in 2020
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Among the TOP5 generic names of terminal antiepileptic drugs in physical pharmacies in Chinese cities, the top four products have sales of more than 100 million yuan, and lamotrigine ranks fourth
.
It is worth noting that among the TOP5 products, only Levetiracetam is included in the national centralized procurement
.
.
It is worth noting that among the TOP5 products, only Levetiracetam is included in the national centralized procurement
.
Lamotrigine tablets have fewer companies in the market for consistency evaluation .
Previously, Huahai Pharmaceutical’s lamotrigine tablets were batch-produced under the new registration classification and deemed to have been reviewed .
Hunan Sanjin’s lamotrigine tablets were the second to be reviewed.
.
At the same time, lamotrigine tablets are also the first variety of Guilin Sanjin to be reviewed
.
Previously, Huahai Pharmaceutical’s lamotrigine tablets were batch-produced under the new registration classification and deemed to have been reviewed .
Hunan Sanjin’s lamotrigine tablets were the second to be reviewed.
.
At the same time, lamotrigine tablets are also the first variety of Guilin Sanjin to be reviewed
.
Data source: Minet database, company announcement
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
On December 13, Guilin Sanjin issued an announcement stating that lamotrigine tablets from Hunan Sanjin, a wholly-owned subsidiary, passed the consistency evaluation
.
Lamotrigine is an anti-epileptic drug.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 400 million yuan
.
.
Lamotrigine is an anti-epileptic drug.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 400 million yuan
.
Lamotrigine tablets are a dual sodium channel blocker and glutamate release inhibitor developed by GlaxoSmithKline.
It is mainly used to treat epilepsy.
It was marketed in the United States in 1994 and approved for marketing in China in 1999
.
Lamotrigine tablets from Hunan Sanjin are the first imitation in China
.
It is mainly used to treat epilepsy.
It was marketed in the United States in 1994 and approved for marketing in China in 1999
.
Lamotrigine tablets from Hunan Sanjin are the first imitation in China
.
According to data from Minai.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China’s urban physical pharmacies will have a combined total of more than 400 million yuan in sales of lamotrigine.
The market share of Lanxo SmithKline reaches 86%
.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China’s urban physical pharmacies will have a combined total of more than 400 million yuan in sales of lamotrigine.
The market share of Lanxo SmithKline reaches 86%
.
TOP5 generic names of terminal antiepileptic drugs in physical pharmacies in Chinese cities in 2020
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Among the TOP5 generic names of terminal antiepileptic drugs in physical pharmacies in Chinese cities, the top four products have sales of more than 100 million yuan, and lamotrigine ranks fourth
.
It is worth noting that among the TOP5 products, only Levetiracetam is included in the national centralized procurement
.
.
It is worth noting that among the TOP5 products, only Levetiracetam is included in the national centralized procurement
.
Lamotrigine tablets have fewer companies in the market for consistency evaluation .
Previously, Huahai Pharmaceutical’s lamotrigine tablets were batch-produced under the new registration classification and deemed to have been reviewed .
Hunan Sanjin’s lamotrigine tablets were the second to be reviewed.
.
At the same time, lamotrigine tablets are also the first variety of Guilin Sanjin to be reviewed
.
Previously, Huahai Pharmaceutical’s lamotrigine tablets were batch-produced under the new registration classification and deemed to have been reviewed .
Hunan Sanjin’s lamotrigine tablets were the second to be reviewed.
.
At the same time, lamotrigine tablets are also the first variety of Guilin Sanjin to be reviewed
.
Data source: Minet database, company announcement
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
On December 13, Guilin Sanjin issued an announcement stating that lamotrigine tablets from Hunan Sanjin, a wholly-owned subsidiary, passed the consistency evaluation
.
Lamotrigine is an anti-epileptic drug.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 400 million yuan
.
.
Lamotrigine is an anti-epileptic drug.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 400 million yuan
.
Lamotrigine tablets are a dual sodium channel blocker and glutamate release inhibitor developed by GlaxoSmithKline.
It is mainly used to treat epilepsy.
It was marketed in the United States in 1994 and approved for marketing in China in 1999
.
Lamotrigine tablets from Hunan Sanjin are the first imitation in China
.
It is mainly used to treat epilepsy.
It was marketed in the United States in 1994 and approved for marketing in China in 1999
.
Lamotrigine tablets from Hunan Sanjin are the first imitation in China
.
According to data from Minai.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China’s urban physical pharmacies will have a combined total of more than 400 million yuan in sales of lamotrigine.
The market share of Lanxo SmithKline reaches 86%
.
Hospital hospital hospital pharmacy pharmacy pharmacycom, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China’s urban physical pharmacies will have a combined total of more than 400 million yuan in sales of lamotrigine.
The market share of Lanxo SmithKline reaches 86%
.
TOP5 generic names of terminal antiepileptic drugs in physical pharmacies in Chinese cities in 2020
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Among the TOP5 generic names of terminal antiepileptic drugs in physical pharmacies in Chinese cities, the top four products have sales of more than 100 million yuan, and lamotrigine ranks fourth
.
It is worth noting that among the TOP5 products, only Levetiracetam is included in the national centralized procurement
.
.
It is worth noting that among the TOP5 products, only Levetiracetam is included in the national centralized procurement
.
Lamotrigine tablets have fewer companies in the market for consistency evaluation .
Previously, Huahai Pharmaceutical’s lamotrigine tablets were batch-produced under the new registration classification and deemed to have been reviewed .
Hunan Sanjin’s lamotrigine tablets were the second to be reviewed.
.
At the same time, lamotrigine tablets are also the first variety of Guilin Sanjin to be reviewed
.
Enterprise business enterprisePreviously, Huahai Pharmaceutical’s lamotrigine tablets were batch-produced under the new registration classification and deemed to have been reviewed .
Hunan Sanjin’s lamotrigine tablets were the second to be reviewed.
.
At the same time, lamotrigine tablets are also the first variety of Guilin Sanjin to be reviewed
.
Data source: Minet database, company announcement
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
